Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
Conditions
Interventions
Sacituzumab Govitecan-hziy
Locations
36
Japan
Aichi Cancer Center Hospital
Aichi, Japan
Akita University Hospital
Akita, Japan
Tohoku University Hospital
Aoba-ku, Japan
Hirosaki University Hospital
Aomori, Japan
Kanagawa Cancer Center
Asahi-ku, Japan
Juntendo University Hospital
Bunkyō City, Japan
Start Date
October 20, 2021
Primary Completion Date
May 1, 2026
Completion Date
May 1, 2026
Last Updated
March 25, 2025
NCT07177937
NCT05919264
NCT07181681
NCT07387068
NCT06257264
NCT07360314
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions